Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Testing method for potency of inactivated vaccine against duck Tembusu viral diseases

A duck Tembusu virus and inactivated vaccine technology is applied in the direction of material inspection products, pharmaceutical formulas, preparations for in vivo tests, etc., to achieve accurate results

Active Publication Date: 2016-08-17
BEIJING ACADEMY OF AGRICULTURE & FORESTRY SCIENCES
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the serological potency test method of duck Tembusu virus disease vaccine, there is no report using HI antibody titer assay as a vaccine potency evaluation method

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Testing method for potency of inactivated vaccine against duck Tembusu viral diseases
  • Testing method for potency of inactivated vaccine against duck Tembusu viral diseases
  • Testing method for potency of inactivated vaccine against duck Tembusu viral diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Establishment of Serological Effectiveness Test Method for Duck Tembusu Virus Disease Inactivated Vaccine

[0034] Three batches (201201, 201202, 201203) of duck Tambusu virus disease (HB strain) inactivated vaccines were used to immunize 16- and 42-day-old Peking ducks for the second time at doses of 0.11, 0.33 and 1.0ml / bird, respectively. Blood was collected on the 28th day after the second immunization, and the HI antibody of each duck serum was measured, and 0.5ml / only (containing 100DID) 50 ) dose to attack the virus. Two days after the challenge, blood was collected, serum was separated, and virus isolation was carried out. According to HI antibody titer (<1:5, 1:5, 1:10, 1:20, 1:40, 1:80, 1:160, 1:320 and 1:640), divide each test Corresponding analysis of HI antibody titer and virus isolation results of ducks, analysis of the correlation between HI antibody titer and challenge protection of each group, and formulation of qualified standards for vacci...

Embodiment 2

[0072] Example 2 Duck Tambusu Virus Disease Inactivated Vaccine (HI Antibody Assay) Efficiency Test Age in Days, Immunization Dose, Sampling Time of Ducks (1)

[0073] Inactivated duck Tembusu virus disease vaccine (batch number 201201, developed by the Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agriculture and Forestry and Ruipu (Baoding) Biopharmaceutical Co., Ltd.) was used to immunize 60-day-old duck Tembusu virus HI antibody-negative shelduck ducks 10 rats, 0.5ml / rat, intramuscularly injected into the chest, and 5 non-immune controls were set at the same time. Two weeks after the first immunization, the second immunization was carried out according to the same dose and the same route, and the serum of the ducks was collected 4 weeks after the second immunization, and the serum of the immune ducks was detected using the annotated HI antibody detection method. The HI antibody titers of 5 non-immunized ducks were all less than <1:5, and 9 of 10...

Embodiment 3

[0074] Example 3 Duck Tambusu Virus Disease Inactivated Vaccine (HI Antibody Assay) Efficacy Test Age in Days, Immunization Dose, Sampling Time of Ducks (2)

[0075] Inactivated duck Tembusu virus disease vaccine (batch number 201202, developed by Institute of Animal Husbandry and Veterinary Medicine, Beijing Academy of Agriculture and Forestry Sciences and Ruipu (Baoding) Biopharmaceutical Co., Ltd.) was used to immunize 42-day-old Peking ducks negative for HI antibody of duck Tembusu virus 10 rats, 1.0ml / rat, intramuscularly injected into the chest, and 5 non-immune controls were set at the same time. Two weeks after the first immunization, the same dose and the same route were used for the second immunization, and the serum of the ducks 4 weeks after the second immunization was collected, and the serum of the immune ducks was detected by the HI antibody detection method in the note. The HI antibody titers of 5 non-immunized ducks were all <1:5, and 8 of 10 immunized ducks h...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a serological testing method for the potency of an inactivated vaccine against duck Tembusu viral diseases. According to the method, HI antibody-negative ducks are used and divided into two groups, i.e., an immunized group consisting of ten ducks and a control group consisting of five ducks; each duck in the immunized group receives hypodermic or intramuscular injection of a vaccine against duck Tembusu viral diseases; immunization with an inactivated vaccine is carried out twice, a dosage of 0.5 ml or 1.0 ml per duck is used each time, and secondary immunization is carried out in two weeks after primary immunization; for immunization with a live vaccine, each duck is immunized according to a dosage of a standard vaccine usage amount for poultry once; in 3 to 4 weeks after inoculation, blood is acquired, serum is separated and the titer of an HI antibody is determined; and when the titer of the HI antibody in the ducks of the control group is less than 1: 5 and the titer of the HI antibody in serum of at least seven ducks of the immunized group is no less than 1: 10, it is determined that the potency of the vaccine is qualified in testing. The serological testing method provided by the invention is convenient to operate and accurate in results and can be extensively applied to potency evaluation of vaccines against duck Tembusu viral diseases and formulation of immune procedure in primary-level organizations and vaccine development and examination units.

Description

technical field [0001] The invention relates to a method for testing the efficacy of a veterinary vaccine, in particular to a method for testing the efficacy of a duck Tembusu virus disease vaccine, which belongs to the technical field of testing biological products for animals. Background technique [0002] Duck Tembusu virus disease is a new or sudden infectious disease that occurred in 2010. Its causative agent is Duck Tembusu Virus (DTMUV), which belongs to the Flaviviridae family in terms of virus classification. The main clinical features are a sudden drop in the egg production of laying ducks and a significant increase in the death rate of ducks. The main gross lesions in cases of natural infection and artificial infection are follicle deformation, hemorrhage, liquefaction and spleen volume changes (spleen enlargement in the early stage of infection, splenomegaly in the later stage). zoom out) and the color turns black. The main histological lesions: reduction in the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68A61K49/00
CPCA61K49/0008G01N33/6803
Inventor 刘月焕林健王小蕾杨志远段会娟赵际成刘立新潘洁
Owner BEIJING ACADEMY OF AGRICULTURE & FORESTRY SCIENCES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com